CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership

Contributed by: Business Wire

Logo

Tags

Health

Medical Devices

Biometrics

Health Technology

Clinical Trials

Cardiology

Biotechnology

Phase 2 MOCA II Pivotal Trial

More Like This

CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology

CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients

Chris O'Connell, Chairman, Board of Directors, CorFlow

CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt

PR Newswire associated0

AorticLab Receives FDA Approval to Initiate FLOWer™ Clinical Pivotal Investigation

PR Newswire associated0

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

PR Newswire associated0

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

Business Wire embedded0

CroíValve Announces Funding from Horizon Europe EIC Accelerator